Optimization of a series of multi-isoform PI3 kinase inhibitors.
Optimization of the cellular and pharmacological activity of a novel series of PI3 kinase inhibitors targeting multiple isoforms is described.
Perry
Benjamin
B
UCB, Granta Park, Great Abington, Cambridge CB21 6GS, UK. benjamin.perry@addexpharma.com
Beevers
Rebekah
R
Bennett
Gavin
G
Buckley
George
G
Crabbe
Tom
T
Gowers
Lewis
L
James
Lynwen
L
Jenkins
Kerry
K
Lock
Chris
C
Sabin
Verity
V
Wright
Sara
S
D000284:Administration, Oral; D000818:Animals; D048588:Benzoxazines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D020650:Combinatorial Chemistry Techniques; D020128:Inhibitory Concentration 50; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D008297:Male; D015394:Molecular Structure; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011720:Pyrazoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013329:Structure-Activity Relationship
D048588:Benzoxazines; D007527:Isoenzymes; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011720:Pyrazoles